NEW YORK (360Dx) – CellMax Life has publicized some of the first data that speaks directly to the sensitivity and specificity of its circulating tumor cell-based colorectal cancer test, which is currently only available through its lab in Taiwan, but which the company plans to now bring to the US market.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.